NCT05032144

The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects

A Randomized,Double-blind,Placebo-controlled,Single-ascending Dose Phase Ⅰa Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of STSA-1002 Following Intravenous Infusion in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

A randomized,double-blind,placebo-controlled,single-ascending dose phase Ⅰa study to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of STSA-1002 following intravenous infusion in healthy subjects

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	STSA-1002 injection	Intravenous injection
DRUG	Placebo	Intravenous injection
DRUG	STSA-1002 injection	Intravenous injection
DRUG	Placebo	Intravenous injection
DRUG	STSA-1002 injection	Intravenous injection
DRUG	Placebo	Intravenous injection
DRUG	STSA-1002 injection	Intravenous injection
DRUG	Placebo	Intravenous injection
DRUG	STSA-1002 injection	Intravenous injection
DRUG	Placebo	Intravenous injection

Timeline

• Start date: 2021-09-28
• Primary completion: 2022-03-31
• Completion: 2022-03-31
• First posted: 2021-09-02
• Last updated: 2022-04-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study